Tocolysis with the β2-sympathomimetic fenoterol does not increase the occurrence of infantile hemangioma in preterm and term infants
β2-sympathomimetics are used in obstetrics as tocolytic agents, despite a remarkable profile of side effects. Recently, the β2-sympathomimetic tocolytic drug hexoprenaline was identified as an independent risk factor for the development of infantile hemangioma (IH) in preterm infants. The aim of this study was to evaluate whether this observed effect was applicable to other β2-mimetic tocolytic agents like fenoterol.
Clinical prospectively collected data of all infants born between 2001 and 2012 and admitted to the neonatal intensive care unit (NICU) at Heidelberg University Hospital and respective maternal data were merged. For the current retrospective cohort study, cases (IH) were matched to controls (no IH) at a ratio of 1:4, adjusting for birth weight, gestational age, gender and multiple gestations. Prenatal exposure to fenoterol and perinatal outcome were analyzed in the total cohort and in subgroups.
N = 5070 infants were admitted to our neonatal department, out of which n = 172 infants with IH were identified and compared to n = 596 matched controls. Exposure to fenoterol was not associated with a higher rate of IH in the total matched population (OR 0.926, 95% CI 0.619–1.384) or in a subgroup of neonates < 32 weeks of gestation or with a birth weight < 1500 g (OR 1.127, 95% CI 0.709–1.791). In the total matched population, prenatal exposure to glucocorticoids was associated with a reduced occurrence of IH (OR 0.566, 95% CI 0.332–0.964) and neonates with IH showed a prolonged total hospital stay compared to controls (69 vs. 57 days, p = 0.0033). Known risk factors for IH were confirmed by our large study cohort and included female gender, low birth weight, preterm birth and multiple gestations (all p < 0.005).
Exposure to fenoterol during pregnancy does not increase the occurrence of IH. Further studies are needed to explore differences in the risk profiles of different β2-sympathomimetic tocolytic drugs.
KeywordsPreterm birth Tocolysis β2-sympathomimetics Fenoterol Hemangioma
H Hudalla: protocol/project development, data collection or management, data analysis and manuscript writing/editing. C Karmen: data collection or management. T Bruckner: data collection or management and data analysis. S Wallwiener: manuscript editing. H Fluhr: manuscript editing. Z Michael: manuscript editing. A Freis: manuscript editing. H Maul: manuscript editing. T Strowitzki: manuscript editing. J Pöschl: manuscript editing. RJ Kuon: protocol/project development, data collection or management, data analysis and manuscript writing/editing.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The study was approved by the Heidelberg University institutional review board (Ethikkommission der Medizinischen Fakultät Heidelberg, Alte Glockengießerei 11/1, 69115 Heidelberg, Germany, IRB number: S-094/2013). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Requirement for inform consent has been waived by the Heidelberg University institutional review board (Ethikkommission der Medizinischen Fakultät Heidelberg, IRB number: S-094/2013) due to the retrospective nature of the study and pseudonymization of data.
- 2.Martin JA, Hamilton BE, Ventura SJ et al (2013) Births: final data for 2011. Natl Vital Stat Rep 62(1):1–69–1–72Google Scholar
- 8.Frieden IJ, Haggstrom AN, Drolet BA et al (2005) Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7–9, 2005, Bethesda, Maryland, USA. In: Pediatr Dermatol, pp 383–406Google Scholar
- 23.Kawabata H, Tran M, Hines P (2004) Using SAS® to match cases for case control studies. SUGI 29. Princeton, New Jersey, 173–29Google Scholar